IRE1-alpha inhibitors (Quentis Therapeutics)

N/A

Report date: 2025/03/20 15:05:45
NME

Base Information

Drug NameIRE1-alpha inhibitors (Quentis Therapeutics)
Drug Alias NameIRE1-alpha inhibitors (Weill Medical College)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase/endoribonuclease IRE1 inhibitors
TargetsSerine/threonine-protein kinase/endoribonuclease IRE1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesWeill Medical College of Cornell University
China Registration ClassN/A

Develop Information

Active CompaniesQuentis Therapeutics Inc
Inactive CompaniesWeill Medical College of Cornell University
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A